Skip to content
value.today

Neurovance, Inc.

Total raised
$27 M
1 round on record
Latest round
$27 M
Oct 2012
First round on record
Oct 2012
Today
Private
No later event on record

Funding rounds

1 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Neurovance, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Oct 2012$27 MNo. 1$10 to $50 million

Neurovance, Inc.: Raise no. 1, Oct 2012

Investors in this round

7 investors had bought by the notice of Jun 29, 2015: 7 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$27 M of $27 M offered
Smallest investment taken
$16,345
What was sold
equity
Exemption claimed
  • Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last
more than a year
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
Estimates
the notice marks payments to its own people as estimates
The company
Corporation, incorporated in Delaware

People named in the notice

  • Albert L. Sokol · Executive Officer · Secretary
  • Anthony A. McKinney · Executive Officer, Director · President and CEO
  • Brigitte T. Robertson · Executive Officer · Chief Medical Officer
  • Franklin P. Bymaster · Executive Officer · Chief Scientific Officer
  • William T. Pappafotopoulos · Executive Officer · Chief Operating Officer
  • Brigitte P. Smith · Director
  • Campbell P. Murray · Director
  • Daniel P. Omstead · Director
  • Paul P. Weiss · Director
  • Timothy J. Barberich · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Remarks in the notice

  • On the amounts: “Closed in 7 tranches. 1: $2,999,999 closed 10/11/12; 2: $2,999,999 closed 4/23/13; 3: $1,500,000 closed 10/10/13; 4: $3,000,003 closed 3/14/14; 5: $4,000,000 closed 8/29/14; 6: $5,500,000 closed 3/18/15; 7: $6,499,995 closed 6/26/15.”

Signed by Albert L. Sokol, Secretary. Source: SEC Form D and 7 amendments, newest notice filed Jun 29, 2015. Read the notice at the SEC.

equitySEC

Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Neurovance, Inc. had no revenue when it filed its newest notice of a funding round (Jun 2015).

    SEC Form D (revenue range) · Jun 2015

  • The industry group it chose in its notices: Other Technology.

    SEC Form D · Jun 2015

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Neurovance, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 7 investors.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Neurovance, Inc.
NameRoleNamed in
Albert L. SokolSecretaryJun 2015
Anthony A. McKinneyPresident and CEOJun 2015
Brigitte T. RobertsonChief Medical OfficerJun 2015
Franklin P. BymasterChief Scientific OfficerJun 2015
William T. PappafotopoulosChief Operating OfficerJun 2015
Walter T. PiskorskiChief Operating OfficerMar 2015
Timothy T. HsuExecutive officerAug 2014
Pierre J. TranExecutive officerApr 2013
Thomas A. SheaExecutive officerApr 2013
Anthony A. McKinneyPresident and CEOJun 2015
Brigitte P. SmithDirectorJun 2015
Campbell P. MurrayDirectorJun 2015
Daniel P. OmsteadDirectorJun 2015
Paul P. WeissDirectorJun 2015
Timothy J. BarberichDirectorJun 2015
TImothy J. BarberichDirectorMar 2015
Frank P. GentileDirectorAug 2014
Joshua P. FunderDirectorAug 2014